Unlike most research peptides, tesamorelin is an approved medicine — so a searched-for tesamorelin dosage does have a defined answer, but only in a very specific, prescription-controlled context. Tesamorelin is approved in the United States (as Egrifta) for one condition, at a defined amount, available only on prescription. That approved amount is not a general recommendation, and it does not make tesamorelin appropriate for other uses. This article documents what has actually been studied and approved; it is a review of published research and regulatory status, not dosing guidance.
What is tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the body's own release of growth hormone. It was approved by the US FDA in 2010 (as Egrifta) for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and has since been reformulated (Egrifta SV; and Egrifta WR / F8, approved 2025). It is not approved by the MHRA or EMA, and PepSource supplies it as a research reagent only.
Is there an established tesamorelin dosage?
Yes — but narrowly. For its single licensed indication, the FDA-approved amount is 2 mg by subcutaneous injection once daily. Crucially:
- This approved amount applies only to adults with HIV-associated lipodystrophy, diagnosed and supervised by a clinician.
- It is not an approval or recommendation for weight loss, body-composition or anti-ageing use in the general population.
- It is a US approval; tesamorelin is not licensed by the MHRA or EMA.
An approved dose for one diagnosis is not a general-purpose dose, and quoting it here is regulatory fact, not a recommendation.
Tesamorelin dosage investigated in human clinical research
| Study | Participants | Quantity investigated | Frequency | Route | Duration | Primary focus |
|---|---|---|---|---|---|---|
| Pivotal Phase 3, Falutz et al., NEJM 2007 | Adults with HIV and abdominal fat accumulation | 2 mg vs placebo | Once daily | Subcutaneous | 26 weeks | Change in visceral adipose tissue (VAT) |
| Confirmatory Phase 3 programme (Falutz et al., 2010) | Adults with HIV lipodystrophy | 2 mg | Once daily | Subcutaneous | Up to 52 weeks (with extension) | VAT reduction & durability |
| FDA-approved label (Egrifta) | Licensed indication | 2 mg | Once daily | Subcutaneous | Ongoing while indicated | Approved dosing for HIV lipodystrophy |
The pivotal evidence comes from the Phase 3 programme reported by Falutz and colleagues in the New England Journal of Medicine (2007) and confirmatory trials. These studied 2 mg of tesamorelin, injected subcutaneously once daily, in adults with HIV-associated abdominal fat accumulation, and reported a statistically significant reduction in visceral adipose tissue (on the order of roughly 15% from baseline) versus placebo over 26 weeks. The 2 mg once-daily amount used in these trials is the amount that became the approved dose.
Dose-escalation research
Tesamorelin's approved regimen is a fixed 2 mg once-daily amount rather than a stepped escalation like the incretin drugs. Early clinical development explored the GHRH-analogue's activity before the pivotal trials settled on 2 mg daily as the studied amount. This describes the development pathway and approved regimen, not an instruction to escalate or self-administer.
Preclinical (animal and laboratory) research
As a GHRH analogue, tesamorelin's mechanism (stimulating pituitary growth-hormone release) was characterised in pharmacology studies before human trials. Because tesamorelin progressed to approval on the strength of its human data, the clinically relevant quantitative information is the human 2 mg once-daily amount. Any animal pharmacology amounts are body-weight-based and cannot be interpreted as an equivalent human dose.
What did different dosage groups show?
The pivotal trials compared 2 mg once-daily tesamorelin against placebo (rather than several active amounts), and the tesamorelin group showed a significant reduction in visceral adipose tissue while placebo did not. Effects on visceral fat tended to reverse after stopping treatment, which is why the approved use is ongoing while indicated. This is reported as trial outcome, not as a rationale for choosing an amount.
Safety and adverse events reported in research
Reported and labelled adverse effects of tesamorelin include injection-site reactions, joint pain (arthralgia) and musculoskeletal effects, fluid retention/oedema, and changes in glucose tolerance and IGF-1 levels (expected with growth-hormone-axis stimulation). Because it raises growth-hormone signalling, the approved label includes cautions around glucose and certain contraindications. These effects are meaningful and are one reason the medicine is prescription-controlled and monitored. Negative and metabolic effects should not be minimised.
What the research does not tell us
- The approved 2 mg once-daily amount applies to one specific HIV-related diagnosis — it is not evidence for general body-composition or anti-ageing use.
- Tesamorelin is not approved by the MHRA or EMA; the approval described is US-only.
- Long-term data in people without HIV lipodystrophy is not the basis of the approval.
- Animal pharmacology amounts cannot be converted into a human dose.
Tesamorelin research timeline
- 2007 — Pivotal Phase 3 results (2 mg once daily) published in the New England Journal of Medicine.
- 2010 — FDA approves tesamorelin (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy at 2 mg subcutaneously once daily.
- 2019 / 2025 — Reformulations approved (Egrifta SV; Egrifta WR / F8), keeping the 2 mg once-daily amount.
Key takeaway
Tesamorelin has a defined, studied and FDA-approved amount — 2 mg by subcutaneous injection once daily — but only for adults with HIV-associated lipodystrophy, as a prescription medicine, under medical supervision, and only in the United States (not MHRA/EMA-approved). The pivotal trials studied that 2 mg daily amount and reported reduced visceral fat versus placebo. This is regulatory and research fact for a specific diagnosis — not a personal dosing recommendation, and PepSource supplies tesamorelin for laboratory research use only.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359–2370. PubMed: PMID 18057338.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled Phase 3 results. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291–4304. PubMed: PMID 20554713.
- US Food and Drug Administration. Egrifta (tesamorelin for injection) prescribing information — approved for HIV-associated lipodystrophy at 2 mg subcutaneously once daily. FDA drug approvals: accessdata.fda.gov.